Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Other Non-Current Assets (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Other Non-Current Assets for 3 consecutive years, with $2000.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Other Non-Current Assets fell 66.67% year-over-year to $2000.0, compared with a TTM value of $2000.0 through Sep 2024, down 66.67%, and an annual FY2023 reading of $27000.0, down 99.98% over the prior year.
  • Other Non-Current Assets was $2000.0 for Q3 2024 at Oramed Pharmaceuticals, roughly flat from $2000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $111.5 million in Q4 2022 and bottomed at $2000.0 in Q2 2024.
  • Average Other Non-Current Assets over 3 years is $15.9 million, with a median of $7000.0 recorded in 2023.
  • The sharpest move saw Other Non-Current Assets crashed 99.98% in 2023, then tumbled 66.67% in 2024.
  • Year by year, Other Non-Current Assets stood at $111.5 million in 2022, then plummeted by 99.98% to $27000.0 in 2023, then plummeted by 92.59% to $2000.0 in 2024.
  • Business Quant data shows Other Non-Current Assets for ORMP at $2000.0 in Q3 2024, $2000.0 in Q2 2024, and $7000.0 in Q1 2024.